25 XP   0   0   10

Lyra Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Lyra Therapeutics Inc together

PenkeI guess you are interested in Lyra Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lyra Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lyra Therapeutics Inc

I send you an email if I find something interesting about Lyra Therapeutics Inc.

Quick analysis of Lyra Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Lyra Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.50
Expected worth in 1 year
$1.64
How sure are you?
29.4%

+ What do you gain per year?

Total Gains per Share
$0.15
Return On Investment
2.7%

For what price can you sell your share?

Current Price per Share
$5.41
Expected price per share
$3.965 - $6.99
How sure are you?
50%

1. Valuation of Lyra Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$5.41

Intrinsic Value Per Share

$-15.79 - $-18.69

Total Value Per Share

$-14.30 - $-17.20

2. Growth of Lyra Therapeutics Inc (5 min.)




Is Lyra Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$89.4m$78.2m$6.2m7.4%

How much money is Lyra Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$15.6m-$12.5m-$3m-19.7%
Net Profit Margin-5,158.1%-34,294.5%--

How much money comes from the company's main activities?

3. Financial Health of Lyra Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#394 / 1019

Most Revenue
#573 / 1019

Most Profit
#639 / 1019

Most Efficient
#918 / 1019

What can you expect buying and holding a share of Lyra Therapeutics Inc? (5 min.)

Welcome investor! Lyra Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Lyra Therapeutics Inc.

What can you expect buying and holding a share of Lyra Therapeutics Inc?

First you should know what it really means to hold a share of Lyra Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Lyra Therapeutics Inc is $5.405. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lyra Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lyra Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.50. Based on the TTM, the Book Value Change Per Share is $0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lyra Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.25-4.7%-0.26-4.9%-0.21-3.9%-0.18-3.3%-0.18-3.3%
Usd Book Value Change Per Share0.091.6%0.040.7%0.193.6%0.091.6%0.091.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.091.6%0.040.7%0.193.6%0.091.6%0.091.6%
Usd Price Per Share5.24-3.82-4.46-5.89-5.89-
Price to Earnings Ratio-5.16--3.67--5.72--10.32--10.32-
Price-to-Total Gains Ratio60.42-10.88--16.69--30.65--30.65-
Price to Book Ratio3.50-2.65-4.28-5.33-5.33-
Price-to-Total Gains Ratio60.42-10.88--16.69--30.65--30.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.405
Number of shares185
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.040.09
Usd Total Gains Per Share0.040.09
Gains per Quarter (185 shares)6.7116.29
Gains per Year (185 shares)26.8465.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10271706555
2054440130120
3081710195185
40107980261250
501341250326315
601611520391380
701881790456445
802152060521510
902422330586575
1002682600652640

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.012.00.029.4%5.012.00.029.4%5.012.00.029.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%5.012.00.029.4%5.012.00.029.4%5.012.00.029.4%

Fundamentals of Lyra Therapeutics Inc

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 13:57:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lyra Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lyra Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -10,380.8% means that $-103.81 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lyra Therapeutics Inc:

  • The MRQ is -10,380.8%. The company is making a huge loss. -2
  • The TTM is -5,158.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-10,380.8%TTM-5,158.1%-5,222.7%
TTM-5,158.1%YOY-34,294.5%+29,136.3%
TTM-5,158.1%5Y-14,217.5%+9,059.3%
5Y-14,217.5%10Y-14,217.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10,380.8%-197.2%-10,183.6%
TTM-5,158.1%-210.4%-4,947.7%
YOY-34,294.5%-279.3%-34,015.2%
5Y-14,217.5%-436.8%-13,780.7%
10Y-14,217.5%-599.3%-13,618.2%
1.1.2. Return on Assets

Shows how efficient Lyra Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • -10.6% Return on Assets means that Lyra Therapeutics Inc generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lyra Therapeutics Inc:

  • The MRQ is -10.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM-13.3%+2.7%
TTM-13.3%YOY-12.8%-0.6%
TTM-13.3%5Y-13.6%+0.2%
5Y-13.6%10Y-13.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-13.6%+3.0%
TTM-13.3%-12.9%-0.4%
YOY-12.8%-11.9%-0.9%
5Y-13.6%-14.2%+0.6%
10Y-13.6%-16.2%+2.6%
1.1.3. Return on Equity

Shows how efficient Lyra Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • -16.9% Return on Equity means Lyra Therapeutics Inc generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lyra Therapeutics Inc:

  • The MRQ is -16.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.9%TTM-19.0%+2.0%
TTM-19.0%YOY-17.8%-1.2%
TTM-19.0%5Y-18.9%0.0%
5Y-18.9%10Y-18.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.9%-17.0%+0.1%
TTM-19.0%-16.1%-2.9%
YOY-17.8%-15.4%-2.4%
5Y-18.9%-20.0%+1.1%
10Y-18.9%-21.1%+2.2%

1.2. Operating Efficiency of Lyra Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lyra Therapeutics Inc is operating .

  • Measures how much profit Lyra Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -11,285.6% means the company generated $-112.86  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lyra Therapeutics Inc:

  • The MRQ is -11,285.6%. The company is operating very inefficient. -2
  • The TTM is -5,373.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-11,285.6%TTM-5,373.0%-5,912.6%
TTM-5,373.0%YOY-36,400.1%+31,027.1%
TTM-5,373.0%5Y-14,780.9%+9,407.9%
5Y-14,780.9%10Y-14,780.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11,285.6%-286.1%-10,999.5%
TTM-5,373.0%-224.4%-5,148.6%
YOY-36,400.1%-288.4%-36,111.7%
5Y-14,780.9%-475.2%-14,305.7%
10Y-14,780.9%-624.7%-14,156.2%
1.2.2. Operating Ratio

Measures how efficient Lyra Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 113.86 means that the operating costs are $113.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 113.856. The company is inefficient in keeping operating costs low. -1
  • The TTM is 67.395. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ113.856TTM67.395+46.462
TTM67.395YOY340.531-273.136
TTM67.3955Y145.622-78.228
5Y145.62210Y145.6220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ113.8562.997+110.859
TTM67.3953.247+64.148
YOY340.5313.766+336.765
5Y145.6225.675+139.947
10Y145.6227.857+137.765

1.3. Liquidity of Lyra Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lyra Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.35 means the company has $5.35 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 5.349. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.294. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.349TTM6.294-0.945
TTM6.294YOY7.473-1.179
TTM6.2945Y9.054-2.760
5Y9.05410Y9.0540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3493.930+1.419
TTM6.2944.251+2.043
YOY7.4735.436+2.037
5Y9.0546.045+3.009
10Y9.0546.363+2.691
1.3.2. Quick Ratio

Measures if Lyra Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 9.35 means the company can pay off $9.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 9.346. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.364. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.346TTM10.364-1.019
TTM10.364YOY8.434+1.931
TTM10.3645Y10.106+0.259
5Y10.10610Y10.1060.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3463.629+5.717
TTM10.3644.065+6.299
YOY8.4345.397+3.037
5Y10.1065.993+4.113
10Y10.1066.277+3.829

1.4. Solvency of Lyra Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lyra Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lyra Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.37 means that Lyra Therapeutics Inc assets are financed with 37.3% credit (debt) and the remaining percentage (100% - 37.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 0.373. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.296. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.373TTM0.296+0.076
TTM0.296YOY0.259+0.037
TTM0.2965Y0.474-0.177
5Y0.47410Y0.4740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3730.332+0.041
TTM0.2960.334-0.038
YOY0.2590.268-0.009
5Y0.4740.366+0.108
10Y0.4740.390+0.084
1.4.2. Debt to Equity Ratio

Measures if Lyra Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 59.5% means that company has $0.59 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 0.595. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.430. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.595TTM0.430+0.164
TTM0.430YOY0.374+0.056
TTM0.4305Y0.349+0.081
5Y0.34910Y0.3490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5950.381+0.214
TTM0.4300.390+0.040
YOY0.3740.334+0.040
5Y0.3490.434-0.085
10Y0.3490.466-0.117

2. Market Valuation of Lyra Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lyra Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -5.16 means the investor is paying $-5.16 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lyra Therapeutics Inc:

  • The EOD is -5.326. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.164. Based on the earnings, the company is expensive. -2
  • The TTM is -3.668. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.326MRQ-5.164-0.163
MRQ-5.164TTM-3.668-1.496
TTM-3.668YOY-5.723+2.055
TTM-3.6685Y-10.318+6.650
5Y-10.31810Y-10.3180.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.326-2.315-3.011
MRQ-5.164-2.560-2.604
TTM-3.668-2.664-1.004
YOY-5.723-4.122-1.601
5Y-10.318-6.258-4.060
10Y-10.318-6.108-4.210
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lyra Therapeutics Inc:

  • The EOD is -4.068. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.944. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.551. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.068MRQ-3.944-0.124
MRQ-3.944TTM-3.551-0.392
TTM-3.551YOY-6.420+2.868
TTM-3.5515Y-7.004+3.452
5Y-7.00410Y-7.0040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.068-3.067-1.001
MRQ-3.944-3.251-0.693
TTM-3.551-3.545-0.006
YOY-6.420-5.595-0.825
5Y-7.004-8.315+1.311
10Y-7.004-8.708+1.704
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lyra Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.50 means the investor is paying $3.50 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lyra Therapeutics Inc:

  • The EOD is 3.611. Based on the equity, the company is fair priced.
  • The MRQ is 3.501. Based on the equity, the company is fair priced.
  • The TTM is 2.645. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.611MRQ3.501+0.110
MRQ3.501TTM2.645+0.855
TTM2.645YOY4.276-1.631
TTM2.6455Y5.331-2.685
5Y5.33110Y5.3310.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.6111.905+1.706
MRQ3.5012.111+1.390
TTM2.6452.095+0.550
YOY4.2762.836+1.440
5Y5.3313.443+1.888
10Y5.3313.794+1.537
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lyra Therapeutics Inc.

3.1. Institutions holding Lyra Therapeutics Inc

Institutions are holding 84.648% of the shares of Lyra Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Perceptive Advisors LLC24.27091.66391275756200
2023-09-30Nantahala Capital Management, LLC7.70541.35284050218926762.3418
2023-09-30Citadel Advisors Llc5.41930.00242848564-614-0.0216
2023-09-30Samsara BioCapital, LLC5.28943.3276278026100
2023-09-30PURA VIDA INVESTMENTS, LLC2.68871.045141324200
2023-12-31Ikarian Capital, LLC2.38640.6155125438400
2023-12-31Armistice Capital, LLC2.06990.07781088000-462000-29.8065
2023-09-30VR Adviser, LLC1.75820.380492417000
2023-09-30Vanguard Group Inc1.64440.0001864332733969.2796
2023-09-30Parkman Healthcare Partners LLC1.18920.4478625056250564.176
2023-12-31Woodline Partners LP1.14140.03425999755999750
2023-09-30Geode Capital Management, LLC0.58730.0001308690159850107.3972
2023-12-31Ensign Peak Advisors Inc0.57370.003130153300
2023-09-30Millennium Management LLC0.5010.00052633492633490
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC0.47550.0334249939159366.8102
2023-09-30Susquehanna International Group, LLP0.30980.00011628601509751270.2987
2023-12-31Bridgeway Capital Management, LLC0.26980.015914180000
2023-12-31Two Sigma Investments LLC0.25230.0016132606116186707.5883
2023-09-30Alyeska Investment Group, L.P.0.24890.0035130839-350607-72.8237
2023-09-30Bank of America Corp0.23960.00011259541314011.6475
Total 59.02119.005831023334+697318+2.2%

3.2. Funds holding Lyra Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.73210.000399101700
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.6840.00239136091992.4071
2024-01-31Fidelity Extended Market Index0.3140.002317968200
2023-12-31Bridgeway Ultra-Small Company Market0.24450.394513990000
2024-01-31Fidelity Total Market Index0.10450.0003597971006420.2361
2024-01-31DFA US Micro Cap I0.09270.00365305000
2024-01-31Fidelity Series Total Market Index0.07540.000343122497013.0268
2024-02-29iShares Micro-Cap ETF0.07360.02434213616434.0575
2024-01-31Fidelity Nasdaq Composite Index0.06350.00113634800
2023-12-31Northern Trust Extended Eq Market Idx0.05290.002730261394714.9996
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05290.002730261394714.9996
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.05120.00242930400
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04110.002523535440.1873
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.04080.00042336400
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.04080.000323364-452793-95.0932
2024-01-31Spartan Total Market Index Pool E0.0390.00042231800
2024-02-29Dimensional US Core Equity 2 ETF0.03750.00042145500
2023-12-31Mandarine Global Microcap M EUR0.02450.27813990139900
2024-02-29Dimensional US Small Cap ETF0.02230.00091275200
2023-12-31SSgA U.S. Extended Market Index Class I0.02130.0024122007300148.9796
Total 3.80860.72182179216-397689-18.2%

3.3. Insider Transactions

Insiders are holding 1.177% of the shares of Lyra Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-10Harlan WaksalBUY250002.96
2023-05-31Nbvm Gp, LlcBUY18054162.43
2023-05-31Perceptive Advisors LlcBUY36108322.49

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Lyra Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0870.036+139%0.194-55%0.088-2%0.088-2%
Book Value Per Share--1.4971.416+6%1.310+14%0.966+55%0.966+55%
Current Ratio--5.3496.294-15%7.473-28%9.054-41%9.054-41%
Debt To Asset Ratio--0.3730.296+26%0.259+44%0.474-21%0.474-21%
Debt To Equity Ratio--0.5950.430+38%0.374+59%0.349+70%0.349+70%
Dividend Per Share----0%-0%-0%-0%
Eps---0.254-0.262+3%-0.210-17%-0.180-29%-0.180-29%
Free Cash Flow Per Share---0.332-0.269-19%-0.182-45%-0.161-51%-0.161-51%
Free Cash Flow To Equity Per Share---0.0150.006-376%-0.183+1083%-0.011-32%-0.011-32%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---18.692--------
Intrinsic Value_10Y_min---15.793--------
Intrinsic Value_1Y_max---0.927--------
Intrinsic Value_1Y_min---0.910--------
Intrinsic Value_3Y_max---3.506--------
Intrinsic Value_3Y_min---3.332--------
Intrinsic Value_5Y_max---6.954--------
Intrinsic Value_5Y_min---6.392--------
Market Cap322911455.500+3%313053844.000228069284.250+37%266155510.500+18%351830630.200-11%351830630.200-11%
Net Profit Margin---103.808-51.581-50%-342.945+230%-142.175+37%-142.175+37%
Operating Margin---112.856-53.730-52%-364.001+223%-147.809+31%-147.809+31%
Operating Ratio--113.85667.395+69%340.531-67%145.622-22%145.622-22%
Pb Ratio3.611+3%3.5012.645+32%4.276-18%5.331-34%5.331-34%
Pe Ratio-5.326-3%-5.164-3.668-29%-5.723+11%-10.318+100%-10.318+100%
Price Per Share5.405+3%5.2403.818+37%4.455+18%5.889-11%5.889-11%
Price To Free Cash Flow Ratio-4.068-3%-3.944-3.551-10%-6.420+63%-7.004+78%-7.004+78%
Price To Total Gains Ratio62.326+3%60.42310.875+456%-16.692+128%-30.651+151%-30.651+151%
Quick Ratio--9.34610.364-10%8.434+11%10.106-8%10.106-8%
Return On Assets---0.106-0.133+25%-0.128+20%-0.136+28%-0.136+28%
Return On Equity---0.169-0.190+12%-0.178+5%-0.189+12%-0.189+12%
Total Gains Per Share--0.0870.036+139%0.194-55%0.088-2%0.088-2%
Usd Book Value--89420000.00084581750.000+6%78290500.000+14%57695235.294+55%57695235.294+55%
Usd Book Value Change Per Share--0.0870.036+139%0.194-55%0.088-2%0.088-2%
Usd Book Value Per Share--1.4971.416+6%1.310+14%0.966+55%0.966+55%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.254-0.262+3%-0.210-17%-0.180-29%-0.180-29%
Usd Free Cash Flow---19845000.000-16087750.000-19%-10887250.000-45%-9648294.118-51%-9648294.118-51%
Usd Free Cash Flow Per Share---0.332-0.269-19%-0.182-45%-0.161-51%-0.161-51%
Usd Free Cash Flow To Equity Per Share---0.0150.006-376%-0.183+1083%-0.011-32%-0.011-32%
Usd Market Cap322911455.500+3%313053844.000228069284.250+37%266155510.500+18%351830630.200-11%351830630.200-11%
Usd Price Per Share5.405+3%5.2403.818+37%4.455+18%5.889-11%5.889-11%
Usd Profit---15156000.000-15670000.000+3%-12588750.000-17%-10750000.000-29%-10750000.000-29%
Usd Revenue--146000.000389500.000-63%1536000.000-90%469823.529-69%469823.529-69%
Usd Total Gains Per Share--0.0870.036+139%0.194-55%0.088-2%0.088-2%
 EOD+6 -2MRQTTM+18 -15YOY+16 -175Y+12 -2110Y+12 -21

4.2. Fundamental Score

Let's check the fundamental score of Lyra Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.326
Price to Book Ratio (EOD)Between0-13.611
Net Profit Margin (MRQ)Greater than0-103.808
Operating Margin (MRQ)Greater than0-112.856
Quick Ratio (MRQ)Greater than19.346
Current Ratio (MRQ)Greater than15.349
Debt to Asset Ratio (MRQ)Less than10.373
Debt to Equity Ratio (MRQ)Less than10.595
Return on Equity (MRQ)Greater than0.15-0.169
Return on Assets (MRQ)Greater than0.05-0.106
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Lyra Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose5.400
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Debt  -30,33410,406-19,928-32,745-52,67334,113-18,56023,0884,528



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets142,600
Total Liabilities53,180
Total Stockholder Equity89,420
 As reported
Total Liabilities 53,180
Total Stockholder Equity+ 89,420
Total Assets = 142,600

Assets

Total Assets142,600
Total Current Assets104,821
Long-term Assets37,779
Total Current Assets
Cash And Cash Equivalents 22,353
Short-term Investments 80,400
Other Current Assets 2,068
Total Current Assets  (as reported)104,821
Total Current Assets  (calculated)104,821
+/-0
Long-term Assets
Property Plant Equipment 35,276
Long-term Assets Other 1,111
Long-term Assets  (as reported)37,779
Long-term Assets  (calculated)36,387
+/- 1,392

Liabilities & Shareholders' Equity

Total Current Liabilities19,597
Long-term Liabilities33,583
Total Stockholder Equity89,420
Total Current Liabilities
Short-term Debt 5,434
Accounts payable 3,131
Other Current Liabilities 9,374
Total Current Liabilities  (as reported)19,597
Total Current Liabilities  (calculated)17,939
+/- 1,658
Long-term Liabilities
Capital Lease Obligations 26,881
Long-term Liabilities  (as reported)33,583
Long-term Liabilities  (calculated)26,881
+/- 6,702
Total Stockholder Equity
Common Stock57
Retained Earnings -311,355
Accumulated Other Comprehensive Income 33
Other Stockholders Equity 400,685
Total Stockholder Equity (as reported)89,420
Total Stockholder Equity (calculated)89,420
+/-0
Other
Capital Stock57
Cash and Short Term Investments 102,753
Common Stock Shares Outstanding 57,215
Current Deferred Revenue1,658
Liabilities and Stockholders Equity 142,600
Net Debt 4,528
Net Invested Capital 89,420
Net Working Capital 85,224
Property Plant and Equipment Gross 37,197
Short Long Term Debt Total 26,881



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
14,963
40,766
92,723
87,330
80,830
72,917
76,332
67,762
54,867
47,345
130,035
119,463
109,968
93,868
125,675
120,575
142,600
142,600120,575125,67593,868109,968119,463130,03547,34554,86767,76276,33272,91780,83087,33092,72340,76614,963000
   > Total Current Assets 
0
0
0
10,119
35,540
89,310
83,555
75,917
67,351
70,073
60,886
47,918
40,555
122,381
112,230
100,829
84,799
118,253
104,920
104,821
104,821104,920118,25384,799100,829112,230122,38140,55547,91860,88670,07367,35175,91783,55589,31035,54010,119000
       Cash And Cash Equivalents 
0
0
0
9,808
35,247
86,599
81,555
74,593
66,105
69,046
58,131
45,747
33,755
120,669
109,558
32,550
22,019
54,361
24,850
22,353
22,35324,85054,36122,01932,550109,558120,66933,75545,74758,13169,04666,10574,59381,55586,59935,2479,808000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65,344
60,688
61,789
77,700
80,400
80,40077,70061,78960,68865,344000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
5,000
0
0
0
0
0
0
0
00000005,000000000000000
       Other Current Assets 
0
0
0
311
293
2,711
2,000
1,324
1,246
1,027
2,755
2,171
1,800
1,383
2,343
2,935
2,092
1,800
2,370
2,068
2,0682,3701,8002,0922,9352,3431,3831,8002,1712,7551,0271,2461,3242,0002,711293311000
   > Long-term Assets 
0
0
0
4,844
5,226
3,413
3,775
4,913
5,566
6,259
6,876
6,949
6,790
7,654
7,233
9,139
9,069
7,422
15,655
37,779
37,77915,6557,4229,0699,1397,2337,6546,7906,9496,8766,2595,5664,9133,7753,4135,2264,844000
       Property Plant Equipment 
0
0
0
3,419
3,247
3,084
3,446
4,466
5,237
5,687
6,302
5,858
5,384
4,869
4,361
4,466
3,829
1,980
6,800
35,276
35,2766,8001,9803,8294,4664,3614,8695,3845,8586,3025,6875,2374,4663,4463,0843,2473,419000
       Other Assets 
0
0
0
0
1,979
329
329
2,748
329
572
574
1,091
1,406
2,785
2,872
4,673
0
5,442
0
0
005,44204,6732,8722,7851,4061,0915745723292,7483293291,9790000
> Total Liabilities 
0
0
0
7,635
167,547
5,900
6,416
6,338
5,366
18,833
20,574
20,551
19,189
19,005
26,241
29,214
27,777
27,098
36,336
53,180
53,18036,33627,09827,77729,21426,24119,00519,18920,55120,57418,8335,3666,3386,4165,900167,5477,635000
   > Total Current Liabilities 
0
0
0
5,208
5,158
3,942
4,708
4,884
4,170
5,904
17,773
18,246
17,802
9,872
13,605
14,470
14,154
14,111
19,235
19,597
19,59719,23514,11114,15414,47013,6059,87217,80218,24617,7735,9044,1704,8844,7083,9425,1585,208000
       Short-term Debt 
0
0
0
899
919
943
964
985
1,007
1,029
1,052
1,074
1,097
926
654
1,549
1,900
1,688
1,403
5,434
5,4341,4031,6881,9001,5496549261,0971,0741,0521,0291,007985964943919899000
       Accounts payable 
0
0
0
1,069
1,358
1,146
530
922
1,169
1,899
2,912
3,125
2,408
1,670
2,900
2,616
3,951
4,188
5,054
3,131
3,1315,0544,1883,9512,6162,9001,6702,4083,1252,9121,8991,1699225301,1461,3581,069000
       Other Current Liabilities 
0
0
0
110
153
109
109
149
63
-9,024
3,968
4,258
4,237
5,465
7,321
9,030
6,793
6,738
11,052
9,374
9,37411,0526,7386,7939,0307,3215,4654,2374,2583,968-9,02463149109109153110000
   > Long-term Liabilities 
0
0
0
2,427
162,389
1,958
1,708
1,454
1,196
12,929
2,801
2,305
1,387
9,133
12,636
14,744
13,623
12,987
17,101
33,583
33,58317,10112,98713,62314,74412,6369,1331,3872,3052,80112,9291,1961,4541,7081,958162,3892,427000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
12,000
2,145
1,926
1,288
9,130
12,633
14,077
0
12,987
0
0
0012,987014,07712,6339,1301,2881,9262,14512,000000000000
       Deferred Long Term Liability 
0
0
0
0
1,650
0
0
0
0
12,000
0
0
1,288
9,130
13,176
0
13,432
0
0
0
00013,432013,1769,1301,2880012,00000001,6500000
> Total Stockholder Equity
0
0
0
7,328
-126,781
86,823
80,914
74,492
67,551
57,499
47,188
34,316
28,156
111,030
93,222
80,754
66,091
98,577
84,239
89,420
89,42084,23998,57766,09180,75493,222111,03028,15634,31647,18857,49967,55174,49280,91486,823-126,7817,328000
   Common Stock
0
0
0
6
-39,742
13
13
13
13
13
13
13
13
32
32
32
32
50
50
57
575050323232321313131313131313-39,7426000
   Retained Earnings Total Equity000-264,9300-219,674-214,893-200,40900-168,725-157,686-149,8840000000
   Accumulated Other Comprehensive Income 
0
0
0
-2,829
-2,837
-2,850
-87,330
0
0
0
0
0
0
0
0
10
-12
-27
-7
33
33-7-27-121000000000-87,330-2,850-2,837-2,829000
   Capital Surplus 
0
0
0
0
5,208
0
0
224,363
225,224
226,211
0
0
228,552
325,891
325,891
0
331,001
0
0
0
000331,0010325,891325,891228,55200226,211225,224224,363005,2080000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
137,908
8,045
133,466
223,764
224,363
225,224
226,211
226,955
227,700
228,552
325,891
327,630
329,387
331,001
379,102
380,395
400,685
400,685380,395379,102331,001329,387327,630325,891228,552227,700226,955226,211225,224224,363223,764133,4668,045137,908000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,558
Cost of Revenue-278
Gross Profit1,2801,280
 
Operating Income (+$)
Gross Profit1,280
Operating Expense-66,808
Operating Income-65,528-65,528
 
Operating Expense (+$)
Research Development47,751
Selling General Administrative19,057
Selling And Marketing Expenses0
Operating Expense66,80866,808
 
Net Interest Income (+$)
Interest Income4,094
Interest Expense-0
Other Finance Cost-0
Net Interest Income4,094
 
Pretax Income (+$)
Operating Income-65,528
Net Interest Income4,094
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-62,621-68,435
EBIT - interestExpense = -65,528
-62,621
-62,680
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-65,528-62,621
Earnings Before Interest and Taxes (EBITDA)-65,250
 
After tax Income (+$)
Income Before Tax-62,621
Tax Provision-55
Net Income From Continuing Ops-61,759-62,676
Net Income-62,680
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses67,086
Total Other Income/Expenses Net2,907-4,094
 

Technical Analysis of Lyra Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lyra Therapeutics Inc. The general trend of Lyra Therapeutics Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lyra Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lyra Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.79 < 6.99.

The bearish price targets are: 4.46 > 4.19 > 3.965.

Tweet this
Lyra Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lyra Therapeutics Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lyra Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartLyra Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lyra Therapeutics Inc. The current adx is .

Lyra Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Relative Strength Index (RSI) ChartLyra Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Stochastic Oscillator ChartLyra Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Commodity Channel Index (CCI) ChartLyra Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartLyra Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Williams %R ChartLyra Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Average True Range (ATR) ChartLyra Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily On-Balance Volume (OBV) ChartLyra Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Money Flow Index (MFI) ChartLyra Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lyra Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Lyra Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lyra Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose5.400
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lyra Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Lyra Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lyra Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lyra Therapeutics Inc

I send you an email if I find something interesting about Lyra Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lyra Therapeutics Inc.

Receive notifications about Lyra Therapeutics Inc in your mailbox!